Agtech
PublicA wide-moat seed/chem duopolist priced for steady compounding, sitting on a triple inflection — royalty flip to net out-licensor, the Bayer settlement unlocking corn/cotton licensing, and a 2H26 split that hands the clean-growth Seed business to SpinCo and dumps every legacy liability on Crop-Protection-Co; own the seeds, scrutinize the chem.
Research
The verdict
A wide-moat seed/chem duopolist priced for steady compounding, sitting on a triple inflection — royalty flip to net out-licensor, the Bayer settlement unlocking corn/cotton licensing, and a 2H26 split that hands the clean-growth Seed business to SpinCo and dumps every legacy liability on Crop-Protection-Co; own the seeds, scrutinize the chem.
Corteva is the only pure-play, scaled, vertically-integrated agricultural-inputs company in the world — it sells both the seed and the chemistry that protects it, to the same farmer, through the same channel. It was carved out of DowDuPont in the 2019 three-way split (the ag piece; Dow took materials, DuPont kept specialty chem) and carries the genetics of two storied franchises: Pioneer (corn/soybean germplasm, founded 1926) and Dow AgroSciences (crop chemistry).
Two reported segments:
Business model nuance — the royalty engine. Beyond product sales, Corteva runs a trait out-licensing business that is structurally inflecting. Five years ago it was a net royalty payer of ~$700M/yr (mostly to Bayer for stacked traits); it reaches royalty neutrality in 2026 and targets a $1B net royalty income position by 2035 as it becomes a net out-licensor of Enlist.
Contract structure: seasonal, weather- and commodity-price-sensitive, with a heavy Northern-Hemisphere first-half / Brazil-safrinha cadence — not recurring/subscription. Pricing power is real in seed (genetics differentiation) and thinner in crop protection (generic competition, esp. from off-patent actives sourced from China).
THE headline event: On October 1, 2025, the board unanimously approved a tax-free separation into two public companies — "New Corteva" (the Crop Protection business, ~$7.8B sales) and "SpinCo" (the Seed business, ~$9.9B sales), targeted for 2H 2026. CEO Chuck Magro moves to run SpinCo (Seed); Chair Greg Page chairs New Corteva.
Map: upstream inputs → Corteva → channel → farmer.
Named competitors along the chem chain: Bayer (Crop Science), Syngenta Group (owned by ChemChina/Sinochem), BASF, FMC, UPL.
Chokepoints: (1) Chinese AI supply for crop protection; (2) Brazilian Real / FX as a recurring margin swing; (3) channel-inventory destocking cycles (the 2023–24 crop-protection destocking was the single biggest recent earnings drag). The Seed side is the insulated part of the chain — which is exactly why the split puts Seed in the cleaner vehicle.
Moat verdict: wide, and asymmetric across the two segments. Morningstar carries CTVA with a wide-moat rating.
The most important moat fact for the thesis: the royalty position flip. Going from a ~$700M/yr net royalty payer to neutral (2026) to a targeted $1B net out-licensor (2035) is a structural margin tailwind that is internally generated — it doesn't need crop prices to cooperate.
By segment (FY2025):
| Segment | Net sales | YoY | Op. EBITDA | YoY | Margin |
|---|---|---|---|---|---|
| Seed | $9.9B | +4% | $2.6B | +19% | 26.6% |
| Crop Protection | $7.5B | +2% (+3% org) | $1.35B | +6% | 18.0% |
| Total | $17.4B | +3% (+4% org) | $3.85B | +14% | ~22% |
Trend & cause: Seed is the margin-expansion story — +19% EBITDA on +4% sales = operating leverage + the royalty tailwind + price/mix in corn. Crop Protection is the recovery story — coming off the brutal 2023–24 channel destocking, +6% EBITDA in 2025 signals the destock is largely behind it, though Latin-American competitive pricing (−10% price in Q3'24, −2% in Q1'26) is still a live drag.
By geography (FY2024, the last full clean year):
| Region | Net sales | % of total |
|---|---|---|
| North America | $8,660M | ~51% |
| Latin America | $3,776M | ~22% |
| EMEA | $3,124M | ~18% |
| Asia Pacific | $1,348M | ~8% |
North America (Corn Belt) is the profit engine; Latin America/Brazil is the swing factor — both the growth upside (safrinha corn area, Argentina recovery) and the volatility source (FX, destocking, generic crop-protection pricing). Q1 2026 already showed the recovery thesis working: net sales $4.91B, +11.1% YoY, organic +7%, Op. EBITDA +21%.
Latest full print — FY2025 (reported Feb 3, 2026):
Q4 2025 specifically: EPS $0.22, in line; revenue $3.91B vs ~$4.24B expected — a ~7.8% miss. Stock dipped ~1.85% pre-market to ~$73.65 on the revenue miss against an otherwise strong full-year.
Most recent quarter — Q1 2026: net sales $4.91B, +11.1% YoY, organic +7%, Op. EBITDA +21%, price −2% (LatAm competition). A clear beat and an acceleration, and management reaffirmed the year.
Read: the full-year signal (record EBITDA, +30% operating EPS, 40% FCF jump) is unambiguously strong and quality-of-earnings-positive on the cash line. The quarterly signal is noisier — a Q4 revenue miss on volume/FX timing, then a strong Q1 rebound. The destocking trough is in the rear-view; the royalty flip and price/mix in seed are carrying margins.
No transcripts in the research layer; synthesized from press releases + call coverage.
Tone arc, last ~3 years:
Things they stopped saying: the heavy "destocking / channel-inventory normalization" language that dominated 2023–24 has faded — itself a positive tell. Recurring new phrases: royalty neutrality (2026), accelerated freedom to operate, the $1B licensing decade-upside, separation into two leaders. The narrative pivot is the signal: from "managing a cyclical trough" to "structurally re-rating the business and splitting it to surface value."
Pure global peers are scarce — that's the point of a pure-play. Multiples are `` with source/date or marked not-sourced. Never fabricated.
| Company | Ticker | Mkt cap (USD) | EV/EBITDA | P/E (fwd) | Div yield | 5yr avg ROE |
|---|---|---|---|---|---|---|
| Corteva | CTVA | ~$57–58B | 13.0x | 20.5x fwd (29.8x ttm) | ~1.0% | n/a |
| FMC | FMC | n/a | ~9x | n/a | n/a | n/a |
| Bayer | BAYRY/BAYN | n/a | n/a | n/a | n/a | n/a |
| Nutrien | NTR | n/a | n/a | n/a | n/a | n/a |
| Mosaic | MOS | n/a | n/a | ~170x ttm (depressed earnings) | n/a | n/a |
| CF Industries | CF | n/a | n/a | ~10x ttm | n/a | n/a |
What the table says: Corteva trades at a clear premium to pure crop-protection (FMC ~9x vs CTVA ~13x EV/EBITDA) — the market is paying up for the integrated seed-led model and the royalty inflection. Fertilizer names (MOS/CF/NTR) are a different business (commodity nutrients, not genetics/chemistry) and are poor multiple comps despite sharing the "ag" label. The cleanest read-through: post-split, SpinCo/Seed should command a premium re-rate (genetics moat, royalty income, no legacy liabilities) while New Corteva/Crop-Protection should trade closer to the FMC ~9x band plus a liability discount. Sum-of-the-parts is the entire bull case for the separation.
Provenance flag: I could not source clean, current EV/EBITDA, ROE, or dividend yields for Bayer/Nutrien/most peers without primary data. Those cells are honestly marked n/a rather than filled with plausible fabrications. A hybrid re-run would pull these.
Pattern of >5% moves and what the market actually reacts to:
What the market reacts to, ranked: (1) Brazil/LatAm crop-protection pricing & destocking, (2) crop-commodity prices (corn/soy), (3) FX (BRL), (4) corporate-action / liability news (the split), (5) the royalty/licensing narrative. It is a cyclical-input stock with a structural-re-rating option embedded — the catalysts that move it most are still the ag cycle, but the thesis catalysts (royalty flip, split) are what could break it out of the cyclical band.
Web-only — no financials.csv/filings to tie out; figures from releases/coverage. Treat as screening-grade, not audited.
Regulatory findings (required sub-section) — per regulatory/regulatory-findings.md (Stage 1):
Built bottom-up from FY2025 actuals + company guidance. All outputs ``; inputs labeled. No forecast.ts create (breadth loop).
Anchors: FY2025 operating EPS $3.34; FY2026 company guidance operating EPS $3.45–$3.70 (midpoint ~$3.58, +7%), Op. EBITDA $4.0–4.2B (+7% mid). Consensus 12-mo target $89.38 (Buy; 15/0/7), range $77–$100, from 21 analysts.
| Year | Bear | Base | Bull | Key input logic |
|---|---|---|---|---|
| FY2026 | $3.40 | $3.58 | $3.72 | Base = guidance midpoint. Bear = LatAm price war deepens / BRL weakness / soft corn. Bull = top of guide + early licensing $ + biologicals. |
| FY2027 | $3.55 | $3.95 | $4.40 | Base — Enlist corn/cotton licensing turns on (post-Bayer, as early as 2027) + continued seed margin expansion + royalty flip fully positive. Bull adds faster licensing ramp. |
| FY2028 | $3.75 | $4.35 | $5.00 | Base — separation complete (2H26); two focused entities with sharper capital allocation; royalty income compounding toward the $1B-by-2035 path; biologicals scaling. Bear = secular crop-protection generic erosion + a Brazil shock. |
Caveat: post-split (2H26), "Corteva EPS" bifurcates into SpinCo (Seed) EPS + New Corteva (Crop Protection) EPS — these projections are pre-split consolidated; the real FY2027–28 exercise is two separate models. The structural point holds: the earnings algorithm is mid-to-high-single-digit organic + a royalty-flip kicker + a one-time SOTP re-rate from the split. Brier forecast to log on a hybrid re-run (not now): "CTVA FY2026 operating EPS ≥ $3.55, p≈0.62."
Bull case. Corteva is a wide-moat, seed-led duopolist that just engineered three simultaneous value unlocks: (1) the royalty flip from −$700M payer to a targeted +$1B net out-licensor — a self-generated margin tailwind independent of crop prices; (2) the $610M Bayer settlement buying ~$1B of decade licensing upside plus freedom to license triple-stack corn (2027) and enter cotton; (3) the 2H26 tax-free split that lets the market separately re-rate a clean, high-margin (26.6% EBITDA) Seed compounder away from a liability-laden crop-protection business — classic SOTP value surfacing. Layer on the biologicals growth (→25% of crop-protection market by 2035), record FY2025 EBITDA (+14%) and FCF (+40%), and a strong Q1'26 (+21% EBITDA), and you have a business transitioning from "cyclical input supplier" to "genetics-IP + royalty annuity." Multiples (13x EV/EBITDA, 20.5x fwd P/E) are full but defensible for the quality, and the split is the catalyst to crack them higher.
Bear case. Three things that could permanently impair or de-rate: (1) Crop-protection secular generic erosion — ~10% global share in a business where Chinese off-patent actives structurally compress price; New Corteva inherits this plus every legacy liability (PFAS up to ~$2B net, chlorpyrifos torts, DuPont pension, FTC/AG antitrust MDL). (2) Ag is cyclical and FX-whipped — the 2023–24 Brazil destocking torched two years of crop-protection earnings; corn/soy price weakness + a Brazilian Real shock could do it again, and the seed-volume growth leans on Brazil safrinha acreage that is itself weather/price-contingent. (3) The split could disappoint — if the market values the combined entity below the SOTP (dis-synergies, stranded costs, a liability-discounted New Corteva that drags), the re-rate thesis fails; recall the stock fell ~9% on the announcement, largely on the liability-allocation question.
Pre-mortem (18 months out, thesis broke): It's late 2027. The split closed but New Corteva trades at a deep liability discount (a fresh PFAS or chlorpyrifos verdict re-priced the tail), SpinCo's premium re-rate underwhelmed because a soft Brazil season + LatAm price war hit seed volumes, and the royalty/licensing ramp slipped (corn licensing slower than the 2027 hope). The "two market leaders" became "a clean small-cap-ish seed company and an orphaned crop-protection company nobody wants." The combined market cap is below pre-split.
Are multiples too high? Fair-to-fullish. 13x EV/EBITDA / 20.5x fwd P/E is a premium to FMC (~9x) that the seed moat + royalty flip earn — but it prices in the inflection working. There's modest margin of safety, not a lot.
Contrarian view (what the market refuses to see): The consensus frames CTVA as a steady ag-cycle compounder with a corporate-action catalyst. The market is under-weighting the royalty annuity — a −$700M-to-+$1B swing is a $1.7B run-rate pre-tax improvement that is structural, high-margin, and largely crop-price-independent. The Seed-Co that emerges in 2H26 could re-rate not as "ag inputs" but as a genetics-IP + royalty business — a categorically higher multiple. Conversely, the market may be too sanguine on New Corteva — bundling all legacy liabilities into the lower-quality, generic-exposed business is a setup for a value-trap, not a value-unlock, on that side.
Dismantling the bull case.
The category-defining gene-edited nitrogen-fixation company with real revenue (>$100M, 2023) and a tier-1 syndicate — but the product only displaces 15-30% of synthetic N, independent university trials largely fail to find a yield benefit, and it has not raised primary capital since its July-2021 $430M / $2B Series D; WATCHING a private name living off a five-year-old round whose terminal value hinges on an unresolved efficacy question.
World's #1 potash producer + #1 ag-retailer, mid-cycle and cheap (~11x fwd P/E, 1.8x levered), self-help via portfolio simplification — a high-quality cyclical you buy near trough, not a compounder; BULLISH-tactical, not structural.
A dead company — Zimeno/Monarch shipped 500 real tractors but never a real business; collapsed into an assignment-for-creditors and an IP-only Caterpillar acqui-hire. Uninvestable; value here is the post-mortem, not a position.